Metsera, Inc.'s (NASDAQ:MTSR) Quiet Period To Expire on March 12th

Metsera's (NASDAQ:MTSR - Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Guggenheim started coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $56.00 target price on the stock. Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "outperform" rating on the stock. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company. Finally, Cantor Fitzgerald began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "overweight" rating on the stock.

Metsera Stock Down 1.7 %

MTSR traded down $0.44 on Monday, hitting $25.03. 454,435 shares of the company's stock were exchanged, compared to its average volume of 582,820. Metsera has a fifty-two week low of $24.19 and a fifty-two week high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.